2008
    November    Phase I Trials with Alpha 7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator XY4083

2007

     October     Mr. Gordon H. Busenbark Named as CFO
     March        First patient in phase II for XY2405
     January     Xytis begins Phase II for XY2405 in TBI
     January     Xytis announces $40 million NIH CRADA
     January     Dr. Vincent F. Simmon named President, CEO

2006
     January     Xytis merges and raises $24.5M

2005

     November  Xytis starts Phase I for XY2401 in SZ
     June         Xytis Licenses XY2405 from Fournier
     January     Xytis Licenses XY2401 from Rotta